Prostate Cancer Trial, Recruiting NCT06318559 Sponsor: Fondazione del Piemonte per l'Oncologia Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06318559
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a written consent form agreeing to take part and to the use of their personal data
  • People who are male and over 40 years of age
  • People who have had an MRI scan of the prostate done following specific guidelines, with results reported using a standard scoring system called PI-RADS version 2
  • People whose MRI scan shows signs that the cancer has started to push against or beyond the outer edge of the prostate
  • People whose prostate cancer has been confirmed by a tissue sample (biopsy) to be a specific common type called acinar prostate cancer, found in the area identified on the MRI
  • People who do not have large (greater than 3 cm), bone, or organ-based cancer spread in the pelvis or abdomen
  • People whose doctors have determined are suitable for surgery to remove the prostate and nearby lymph nodes
  • People who are in good general health and able to carry out daily activities with little to no limitation (confirm with trial site)
  • People with a life expectancy of at least 5 years
  • People who wish to preserve sexual function and who are currently sexually active, with a score above 17 on a standard questionnaire measuring erectile function
  • People whose medical records from before the study are available
  • People who are able to attend all required follow-up appointments and agree to have their data collected

Who may not be able to join:

  • People whose prostate cancer is of a less common or unusual tissue type
  • People whose PSA level was above 100 ng/ml when they were first diagnosed
  • People who are unable to have an MRI scan (for example, due to having a pacemaker or severe claustrophobia), or whose MRI scan is not of good enough quality to create the required 3D images used in this study
  • People who are currently receiving other cancer treatments, including experimental hormone therapies
  • People who have serious or uncontrolled health conditions, including active uncontrolled infections
  • People who have dementia or a psychiatric condition that could make it difficult to follow the study requirements or to understand and sign the consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Enrico Checcucci, MD, Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo

Phone: +390119933632

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Fondazione del Piemonte per l'Oncologia
Registry
ClinicalTrials.gov
Start date
29 June 2022
Est. completion
31 December 2025

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Perioperative surgical oncological outcomes

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov